Medtronic's (MDT) MiniMed 780G AID System Wins New Accolade

Zacks05-22

Medtronic plc’s MDT most advanced automated insulin delivery (AID) system, MiniMed 780G, was recently recognized by the Fast Company in the Best World-Changing Idea, North America category as part of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2437929476?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Z2Y2lgbJQfUa74IVYcsxPA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a","is_english":true,"pubTime":"2024-05-22 21:06","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2437929476","market":"us","top_or_hot":-1,"title":"Medtronic's (MDT) MiniMed 780G AID System Wins New Accolade","media":"Zacks","content":"<div>\n<p>Medtronic plc’s MDT most advanced automated insulin delivery (AID) system, MiniMed 780G, was recently recognized by the Fast Company in the Best World-Changing Idea, North America category as part of ...</p>\n\n<a href=\"https://finance.yahoo.com/news/medtronics-mdt-minimed-780g-aid-130600864.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medtronic's (MDT) MiniMed 780G AID System Wins New Accolade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedtronic's (MDT) MiniMed 780G AID System Wins New Accolade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-22 21:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/medtronics-mdt-minimed-780g-aid-130600864.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Medtronic plc’s MDT most advanced automated insulin delivery (AID) system, MiniMed 780G, was recently recognized by the Fast Company in the Best World-Changing Idea, North America category as part of ...</p>\n\n<a href=\"https://finance.yahoo.com/news/medtronics-mdt-minimed-780g-aid-130600864.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RMD","symbol_name":"瑞思迈","start_time":0,"source_url":"https://finance.yahoo.com/news/medtronics-mdt-minimed-780g-aid-130600864.html","article_id":"2437929476","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Z2Y2lgbJQfUa74IVYcsxPA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2437929476","pubTimestamp":1716383160,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Medtronic plc’s MDT most advanced automated insulin delivery  system, MiniMed 780G, was recently recognized by the Fast Company in the Best World-Changing Idea, North America category as part of the 2024 World Changing Ideas Awards. This marks the fourth consecutive year the company has been featured on the list, with previous honors received for GI Genius, the Micra leadless pacemaker and Medtronic LABS.Fast Company's annual World Changing Ideas list celebrates organizations that pursue innovation for good. The latest development is expected to significantly boost Medtronic’s Diabetes business.Mealtimes prove to be one of the biggest challenges for people living with type 1 diabetes. Medtronic’s MiniMed 780G stands out as the only system to feature meal detection technology that automatically adjusts and corrects sugar levels every five minutes. The system provides insulin to help account for when users occasionally forget to bolus or underestimate the number of carbs in their meals.T","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"RMD":"瑞思迈","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BK4196":"保健护理服务","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4082":"医疗保健设备","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","BK4121":"生命科学工具和服务","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","BK4588":"碎股","MEDP":"Medpace Holdings Inc.","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","MDT":"美敦力","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","BK4504":"桥水持仓","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","BK4548":"巴美列捷福持仓","ACCD":"Accolade, Inc.","HIMS":"Hims & Hers Health Inc.","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC"},"translate_title":"美敦力（MDT）MiniMed 780G辅助系统赢得新荣誉","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD":1,"ACCD":1,"HIMS":1,"MDT":1,"MEDP":1},"content_text":"Medtronic plc’s MDT most advanced automated insulin delivery (AID) system, MiniMed 780G, was recently recognized by the Fast Company in the Best World-Changing Idea, North America category as part of the 2024 World Changing Ideas Awards. This marks the fourth consecutive year the company has been featured on the list, with previous honors received for GI Genius, the Micra leadless pacemaker and Medtronic LABS.\nFast Company's annual World Changing Ideas list celebrates organizations that pursue innovation for good. The latest development is expected to significantly boost Medtronic’s Diabetes business.\nImportance of MiniMed 780G\nMealtimes prove to be one of the biggest challenges for people living with type 1 diabetes. Medtronic’s MiniMed 780G stands out as the only system to feature meal detection technology that automatically adjusts and corrects sugar levels every five minutes. The system provides insulin to help account for when users occasionally forget to bolus or underestimate the number of carbs in their meals.\nThe pump is compatible with an infusion set that can be worn for up to seven days, doubling the wear time of current infusion sets. The MiniMed 780G offers one of the lowest glucose target settings (as low as 100 mg/dL) of any AID system. With this \"treat to target\" approach, the system more closely mirrors the glucose levels of someone not living with diabetes.\nImage Source: Zacks Investment Research\nAvailable in Europe since 2020, the system is said to deliver the strongest clinical outcomes and the best user experience to date within the Medtronic family of pumps. In late April 2023, the MiniMed 780G insulin pump system received the FDA’s approval with the Guardian 4 sensor, which requires no fingersticks while in SmartGuard technology.\nIn January 2024, the MiniMed 780G with the Simplera Sync sensor received CE Mark approval. The disposable, all-in-one continuous glucose monitor is half the size of previous Medtronic sensors and features an improved user experience with a simple, two-step insertion process. Similar to the Guardian 4 sensor, Simplera Sync requires no fingersticks or overtape.\nMore on the News\nA progressive business media brand, Fast Company’s World Changing Ideas Awards this year showcased innovations from around the world across health, education, energy, AI and more. Winners and finalists were selected by a panel of editors and reporters from a pool of more than 1,300 entries across 50 categories. Understanding the personal nature of diabetes, the design of the MiniMed 780G system is tailored to adapt to each individual's unique needs and goals to help reduce the burden of diabetes management.\nMedtronic Diabetes’ spokesperson expressed pleasure in receiving this acknowledgment and asserted the company’s dedication to continuing to empower individuals with the technology they need to thrive with type 1 diabetes.\nIndustry Prospects\nThe global diabetes device market was valued at $33.9 billion in 2023 and is expected to witness a CAGR of 6.5% by 2032, according to a Precedence Research report. \nThe growing prevalence of diabetes among the global population is the primary factor propelling the market’s growth. Other key factors include a rising prevalence of obesity among the population, growing health consciousness, increasing awareness regarding diabetes, technological advancements in diabetes monitoring devices, easy availability of diabetes devices and rising personal disposable income.\nProgress in the Diabetes Business\nIn the last reported third quarter of fiscal 2024, Medtronic’s Diabetes business returned to double-digit growth, mainly from the robust global adoption of the MiniMed 780G system. The business marked a return to growth in the United States with mid-single digits, driven by nearly 50% revenue growth in insulin pumps. 780G’s highly differentiated outcomes are leading to growth in new users, from both multiple daily injections as well as users of competitor systems.\nIn March 2024, a robust set of new clinical and real-world evidence on the MiniMed 780G system from around the world was presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes in Florence, Italy. The data demonstrated that the system's ability to help individuals with type 1 diabetes exceeded the international targets on outcome measures.\nPrice Performance\nIn the past year, MDT shares have dropped 4.8% compared with the industry’s decline of 1.3%.\nZacks Rank and Key Picks\nMedtronic currently carries a Zacks Rank #4 (Sell).\nSome better-ranked stocks in the broader medical space are Hims & Hers Health HIMS, ResMed RMD and Medpace MEDP. Each of them sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks Rank #1 stocks here.\nHims & Hers Heath stock has surged 84.8% in the past year. Estimates for the company’s earnings have risen from 10 cents to 18 cents in 2024 and from 23 cents to 32 cents in 2025 in the past 30 days.\nHIMS’ earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.\nEstimates for ResMed’s fiscal 2024 earnings per share have moved to $7.64 from $7.43 in the past 30 days. Shares of the company decreased 3.2% in the past year compared with the industry’s fall of 1.3%.\nRMD’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 10.9%.\nEstimates for Medpace’s 2024 earnings per share have moved up to $11.29 from $10.53 in the past 30 days. Shares of the company have surged 87.6% in the past year compared with the industry’s 5% growth.\nMEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an average earnings surprise of 30.6%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nMedtronic PLC (MDT) : Free Stock Analysis Report\nResMed Inc. (RMD) : Free Stock Analysis Report\nMedpace Holdings, Inc. (MEDP) : Free Stock Analysis Report\nHims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2437929476"}